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ABSTRACT Despite recent advances in therapeutic options, hepatitis C virus (HCV)
remains a severe global disease burden, and a vaccine can substantially reduce its
incidence. Due to its extremely high sequence variability, HCV can readily escape the
immune response; thus, an effective vaccine must target conserved, functionally im-
portant epitopes. Using the structure of a broadly neutralizing antibody in complex
with a conserved linear epitope from the HCV E2 envelope glycoprotein (residues
412 to 423; epitope I), we performed structure-based design of immunogens to in-
duce antibody responses to this epitope. This resulted in epitope-based immuno-
gens based on a cyclic defensin protein, as well as a bivalent immunogen with two
copies of the epitope on the E2 surface. We solved the X-ray structure of a cyclic im-
munogen in complex with the HCV1 antibody and conﬁrmed preservation of the
epitope conformation and the HCV1 interface. Mice vaccinated with our designed
immunogens produced robust antibody responses to epitope I, and their serum
could neutralize HCV. Notably, the cyclic designs induced greater epitope-speciﬁc re-
sponses and neutralization than the native peptide epitope. Beyond successfully de-
signing several novel HCV immunogens, this study demonstrates the principle that
neutralizing anti-HCV antibodies can be induced by epitope-based, engineered vac-
cines and provides the basis for further efforts in structure-based design of HCV vac-
cines.
IMPORTANCE Hepatitis C virus is a leading cause of liver disease and liver cancer,
with approximately 3% of the world’s population infected. To combat this virus, an
effective vaccine would have distinct advantages over current therapeutic options,
yet experimental vaccines have not been successful to date, due in part to the vi-
rus’s high sequence variability leading to immune escape. In this study, we rationally
designed several vaccine immunogens based on the structure of a conserved
epitope that is the target of broadly neutralizing antibodies. In vivo results in mice
indicated that these antigens elicited epitope-speciﬁc neutralizing antibodies, with
various degrees of potency and breadth. These promising results suggest that a ra-
tional design approach can be used to generate an effective vaccine for this virus.
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Hepatitis C virus (HCV) is a major global health concern, infecting 3% of the world’spopulation (1). The majority of those infected progress to chronic HCV infection,
which often leads to cirrhosis, liver failure, and hepatocellular carcinoma, a deadly liver
cancer (2). Liver transplantation, undertaken for those with cirrhosis and liver cancer,
does not eliminate the virus completely, resulting in viral rebound and infection of the
transplanted liver (2). Despite advances in treatment methods for HCV, including
recently approved direct acting antivirals, high treatment cost and a high rate of
asymptomatic and untreated infections make a prophylactic vaccine necessary for
global control of HCV (1).
After decades of research, as well as several candidates in phase I and phase II
clinical trials (3), no approved HCV vaccine is available. This is in part due to the high
diversity of the virus within individuals, arising from error-prone replication and esti-
mated to be 10-fold greater than that of HIV, leading to generation of a number of viral
quasispecies that allow it to readily escape from the immune response (4). The
identiﬁcation of broadly neutralizing antibodies (bnAbs) that target conserved and
functionally important regions of the E1 and E2 glycoproteins on the viral surface (5),
as well as structural characterization of several bnAb-epitope complexes (6–13), pro-
vides a major opportunity to design vaccines that induce robust antibody responses to
one or more of these epitopes (14). Such structure-based vaccine design approaches
have been explored for other viruses, such as HIV (15, 16), inﬂuenza virus (17, 18), and
respiratory syncytial virus (RSV) (19, 20), with promising results, though in some cases
neutralizing antibodies were not successfully induced in vivo, possibly due to the
epitope’s context on the viral surface (15) or immunological variability among animal
models (20). In the context of HCV, one candidate for immunogen design is the epitope
bound by the bnAb HCV1 (21).
HCV1 was generated by immunization of humanized mice with soluble E2 (21) and
targets a continuous epitope on the surface of E2 (residues 412 to 423, referred to as
epitope I) which is also recognized by a variety of human (22) and murine (23, 24)
monoclonal antibodies (MAbs). Tests of the HCV1 MAb in chimpanzees showed evi-
dence of protection from HCV infection as well as reduction in viral load (25), and in
humans, HCV1 treatment resulted in a signiﬁcant delay in viral rebound, versus that
with a placebo, following liver transplantation (26). Structural characterization of the
HCV1 MAb in complex with this epitope found that epitope I adopts a  hairpin
conformation with a type I=  turn (6), which was later observed in the structures of
MAb AP33 (8) and two other MAbs (9) bound to epitope I. Epitope I is targeted by
neutralizing antibodies that block E2 binding to the human CD81 receptor, which is
required for cell entry, and is distinguished from other CD81-associated sites on E2
because it is a continuous rather than conformational epitope (27); this is supported by
a recent global E2 alanine scanning study that assessed binding determinants using a
panel of 16 E2-targeting MAbs (28). Due to this apparent decoupling and lack of
dependency on the remainder of E2, epitope I is of particular interest for structure-
based immunogen design efforts, as noted by others (14).
Given the low seroreactivity to this epitope in infected humans (2.5% out of 245
patient samples) (29), the lack of initial reported success inducing antibodies in mice
using the linear epitope (21), and its observed ﬂexibility, which has been highlighted in
several recent structural studies (12, 30), we performed rational engineering to stably
present this antibody-bound structure to the immune system and improve the anti-
body response to this conserved epitope. We also designed a novel protein using the
E2 core protein structure (7), generating a bivalent E2 core antigen presenting two
copies of epitope I on its surface. After conﬁrming antibody binding of designs, as well
as atomic-level structure of a cyclic design bound to the HCV1 MAb, we tested the in
vivo immunogenicity of these designs to compare their degrees of effectiveness at
eliciting antibodies that bind epitope I and tested sera of immunized mice for HCV
neutralization of several HCV genotypes.
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RESULTS
Scaffold search and design of cyclic antigens. As noted previously (31), epitope
I is highly conserved across HCV genotypes (Fig. 1A), and key binding residues for HCV1
(6) are nearly fully conserved (L413, 99.8%; N415, 96.6%; G418, 99.8%; and W420, 99.8%,
as determined by comparison of more than 600 E2 sequences downloaded from the
Los Alamos National Laboratory HCV database [32]). To identify proteins to present the
epitope I structure in its  hairpin conformation and type I=  turn, we searched a set
of approximately 7,600 crystal structures of monomeric proteins downloaded from the
Protein Data Bank (PDB) (33) using the FAST structural alignment algorithm (34) for
substructures matching epitope I in the HCV1 MAb-epitope I crystal structure (6). All
structures including matches identiﬁed by FAST (approximately half of the original
structures) were screened for match length, backbone root mean square distance
(RMSD) to the epitope, protein size, and antibody accessibility. To avoid potentially
immunogenic regions in scaffolds that would reduce response to the E2 epitope, we
searched in particular for scaffolds of small size that would also accommodate antibody
binding to the grafted epitope. We found that several structures corresponding to
human -defensins, which are antimicrobial peptides (approximately 30 amino acids in
length) of the innate immune system, were optimal in this regard (Fig. 1B).
With a human -defensin protein identiﬁed as a potential scaffold, we searched a set
of all defensin structures for further candidate scaffolds in that family of proteins. This
was due to experimentally observed self-association of the -defensins (despite its
monomeric bioassembly in the PDB), which are reported to form symmetric dimers via
backbone-mediated interactions between  strands of the monomers (35); based on
the location of the dimerization interface (36), HCV1 MAb binding would be blocked
were the dimerization to take place in the context of the grafted epitope. We identiﬁed
another class of defensins, -defensins, which feature a  hairpin substructure nearly
identical to that of -defensins yet do not appear to stably self-associate (37). These
were not part of the original search set, as all available -defensin structures were
determined by solution nuclear magnetic resonance (NMR) rather than X-ray crystal-
lography. As with -defensins, they include three disulﬁde bonds, yet functional and
structural characterization by NMR has shown that only one of the disulﬁde bonds is
needed for structure and antimicrobial function (38). Based on the capability of these
small (18-residue) cyclic peptides to form stable  hairpin structures nearly identical to
the HCV1-bound epitope structure (Fig. 1C), with an average backbone RMSD among
20 NMR models of 0.9 Å, we generated two cyclic peptide designs (Fig. 1D) comprising
minimal scaffolded structures of this epitope.
Design of a bivalent E2-based antigen. While a high-resolution structure of the
full E2 glycoprotein has yet to be experimentally described, two crystallographic
structures of E2 core are available (7, 39); these correspond to engineered truncated
variants of E2 from two genotypes. These structures have a shared globular fold,
stabilized by numerous disulﬁde bonds, and epitope I, located near the N terminus of
E2, is fully or mostly absent from both structures. Analysis of these structures revealed
a distinctive  hairpin at the same location on their surfaces, consisting of residues 625
to 644 (H77 isolate numbering); in one of the two E2 core structures, this site is directly
engaged by an antibody (39). Given its high structural similarity to epitope I (backbone
RMSD, 0.8 Å) as well as its surface accessibility, we engineered the E2 glycoprotein to
display epitope I at this site, resulting in a bivalent E2-based scaffold with two copies
of epitope I on its surface (Fig. 2). This was performed in the context of a truncated E2
construct, where we removed most of hypervariable region 1 (HVR1), given its immu-
nogenicity and capacity to mutate (40), as well as C-terminal residues that were
disordered in the E2 core crystal structure. This protein, named Truncation 2 (T2), was
tested alongside two control antigens, in addition to E2661 (Fig. 2C): Truncation 1 (T1),
corresponding to wild-type H77 E2 residues 409 to 645 (without the engineered
epitope at amino acids [aa] 629 to 640), and Truncation 3 (T3), with the engineered
epitope I at aa 629 to 640 and residues 409 to 423 removed.
Structure-Based Design of HCV Vaccines Journal of Virology
October 2017 Volume 91 Issue 20 e01032-17 jvi.asm.org 3
 o
n
 N
ovem
ber 16, 2017 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
FIG 1 Scaffold search and design of epitope I immunogens. (A) Amino acid residue propensities in
epitope I, based on over 600 aligned E2 amino acid sequences downloaded from the Los Alamos
National Laboratory HCV database (35) (2008 set). (B) Search of protein crystal structures for epitope I
scaffolds. Antibody accessibility (clash of superposed epitope-bound HCV1 antibody structure with
scaffold) versus protein size is shown for each candidate scaffold (scaffolds with higher antibody clash are
not shown), with three -defensin structures (PDB codes 1ZMM, 1ZMP, and 1ZMQ) shown as red
triangles. (C) Alignment of HCV1-bound E2 epitope I (PDB code 4DGY; green) to an NMR conformer of
cyclic -defensin (PDB code 2M2S; cyan), which was engineered to remove two out of three internal
disulﬁde bonds; HCV1 MAb (tan and light blue surface for heavy and light chains, respectively) is shown
for reference. Backbone root mean square distance (RMSD) between epitope I and matching BTD-2
residues is 0.9 Å. Cyclic residues and those corresponding to key epitope positions L413, G418, and W420
are shown as sticks, with the epitope positions labeled. BTD-2 backbone cyclization is colored red, and
disulﬁde bond is colored yellow. (D) Sequence of BTD-2, and tested linear and cyclic peptides, with
cyclized residues colored as in (C), BTD-2 cysteines that were mutated in the NMR structure to remove
disulﬁde bonds colored gray, and positions L413, G418, and W420 colored green. Linear and C2
constructs contain E2 residues 409 to 425, while C1 contains E2 residues 412 to 423; all tested peptides
include a C-terminal lysine for carrier protein conjugation.
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Antibody binding of designed immunogens. Cyclic epitope I designs were syn-
thesized and tested for binding to the HCV1 MAb using surface plasmon resonance
(SPR) (Fig. 3) to conﬁrm epitope integrity in the context of the cyclization. Though
antibody immobilization and peptide analyte were tested, this did not produce sufﬁ-
cient binding signals for analysis; therefore, immobilized peptide and HCV1 MAb
analyte were used for SPR assays. Both cyclic designs bound HCV1 with measurable
afﬁnities, comparable to that of the linear peptide (within experimental uncertainty);
thus, cyclization maintained the capability of these immunogens to engage HCV1.
To characterize the epitope presentation of the E2 constructs, E2661 and E2 designs
were engineered with a 6His fusion tag, expressed in HEK-293T cells and puriﬁed by
FIG 2 Design of an E2-based epitope I bivalent immunogen. (A) Structure of E2 core (PDB code 4MWF;
magenta), aligned to HCV1-bound epitope I (PDB code 4DGY; green) using residues 629 to 640. HCV1
MAb (tan and light blue surface for heavy and light chains, respectively) is shown for reference. Epitope
residues L413, G418, and W420, as well as corresponding E2 core residues R630, G635, and E637, are
shown as sticks, and epitope positions are labeled. The backbone root mean square distance between
epitope I and matching E2 core residues (aa 629 to 640) is 0.8 Å. (B) Model of HCV1 MAb bound to the
native epitope I site on E2 (aa 412 to 423) as well as engineered epitope I site at aa 629 to 640, with both
sites colored green, and E2 core and MAb colored as in panel A. (C) Tested E2 constructs E2661, T1
(truncated native), T2 (truncated bivalent), and T3 (truncated engineered site only), with E2 epitope I
sequence locations represented as green boxes.
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nickel afﬁnity chromatography. All three truncated E2 designs were expressed at the
expected size (Fig. 4). We tested antibody binding in an enzyme-linked immunosorbent
assay (ELISA) using HCV1 as well as two other neutralizing antibodies, 95-2 and 96-2
(Fig. 5). Antibody 95-2 is related to HCV1 and binds epitope I (21), while 96-2 binds
epitope II (aa 432 to 443) (25); as with HCV1, both were generated using immunization
of E2661 in mice engineered to express human antibodies (HuMAbs; Medarex, Inc.). All
antibodies were engaged by truncated E2 designs T1 to T3, and though there was some
(10-fold) variability in binding to HCV1, binding to 95-2 and 96-2 was more uniform.
As no major loss of binding was observed for any of the designed constructs, presen-
tation of epitope I, as well as the epitope II site, was not disrupted in the context of
these E2-based designs.
Structural characterization of cyclic C1 immunogen bound to HCV1. To conﬁrm
the structure of the designed C1 immunogen, we performed X-ray crystallography to
determine its structure in complex with HCV1 (Fig. 6; Table 1). This structure was
determined at a resolution of 2.26 Å. A careful comparison of our HCV1-C1 complex
structure with the structure of the HCV1 Fab bound to the linear E2 peptide (PDB code
4DGY [6]) revealed preserved binding mode and epitope conformation, as well as
densities for the engineered disulﬁde bond and C-terminal lysine residue (K425) in the
C1 peptide. As predicted, we observed no difference in the interface between HCV1 and
C1 versus the interface between HCV1 and the linear peptide. We did observe a shift
in the conformation of the HCV1 CDR H3 loop in the HCV1-C1 complex crystal structure
(Fig. 6G and H), suggesting possible conformational dynamics of that loop; this may
additionally be attributed to altered loop context in the crystallographic lattices of
these two structures. After superposition of antibody variable (Fv) domains of these
complexes, RMSDs between linear and C1 peptides conﬁrm conservation of the epitope
structure and binding orientation: 0.37 to 0.48 Å for epitope backbone atoms and 0.83
to 1.09 Å for all epitope atoms (ranges represent values from separate calculations
FIG 3 Binding of linear and cyclic peptides to the HCV1 MAb, measured by surface plasmon resonance. Peptides were coupled to bovine serum albumin and
immobilized on the chip surface, and binding was measured using a 2-fold dilution series of HCV1 MAb from 125 to 1.9 nM. Fitting of kinetic binding data (black
lines) was performed using a bivalent analyte model, and calculated KD1 values are shown. KD1 represents the initial 2:1 interaction afﬁnity and is calculated
as kd1/ka1, where ka1 and kd1 are the initial interaction association and dissociation rates, respectively. Standard deviations were calculated from four
independent experiments.
FIG 4 SDS-PAGE gel of puriﬁed T1, T2, T3, and E2661 proteins. All proteins were treated with peptide-
N-glycosidase F (PNGase) to remove glycans, which is the upper band (36 kDa) in each lane (rightmost
lane contains PNGase only). Reference sizes are shown on the left. Measured E2661 and truncated E2 sizes
range from 26 to 31 kDa, corresponding to expected protein sizes.
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using each of the four asymmetric units of the HCV1-C1 structure), with the larger
values for the latter due primarily to Q412, N417, and N423 side chains which are
exposed and not directly engaged by the antibody.
Serum antibody response elicited by designed antigens. To compare the anti-
body responses elicited by engineered epitope I and E2-based antigens, we immunized
mice with the two cyclic epitope I peptides and three truncated E2 antigens, alongside
control antigens E2661 and linear epitope I. Groups of CD1 mice (n  4) were immu-
nized with 50 g of the peptides or puriﬁed E2-based proteins, followed by four 10-g
boosts over approximately 6 weeks. Soluble E2 (E2661) was included as a positive
control based on its previously described immunogenicity (21). Serum samples were
collected 1 week after the ﬁfth immunization, and sera from immunized mice were
tested for epitope I-speciﬁc antibody response using ELISA (Fig. 7). Mice immunized
with the cyclic antigens (C1 and C2) showed strong ELISA reactivity against the epitope
I peptide, whereas immunization of the linear peptides resulted in signiﬁcantly lower
serum responses. The E2661, T1 (truncated wild-type E2), and T2 (bivalent E2) antigens
induced epitope-speciﬁc responses comparable to those obtained with the cyclized
peptides, with some variability among mice within each group. The T3 antigen, with the
native epitope I site removed, induced the lowest epitope-speciﬁc responses among
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FIG 5 Binding of E2661 and designed E2 proteins to neutralizing MAbs HCV1 (A), 95-2 (B), and 96-2 (C)
measured by ELISA. Error bars indicate standard deviations from two independent experiments (per-
formed for E2661 only), and half-maximal binding titer (EC50) was calculated for each interaction by curve
ﬁtting in GraphPad Prism software.
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E2-based constructs, indicating that the transplanted epitope at aa 629 to 640 is lower
in immunogenicity, or antibodies induced by that site do not cross-react with the native
epitope.
Viral neutralization. To determine if the immunized sera could neutralize virus in
vitro, HCV pseudoparticle (HCVpp) neutralization assays were performed. Mouse sera
were tested against HCVpp with H77 E1E2 sequences (Fig. 8; Table 2). Immunization
with either cyclic peptide yielded measurable levels of neutralizing antibodies, with
some variability within each group. However, no detectable neutralizing antibodies
were generated in mice immunized with linear peptides, indicating that the engineered
cyclic variants are superior immunogens. Mice immunized with the E2-based antigens
showed higher neutralizing antibody responses than the peptide antigens, likely due to
the presence of additional epitopes outside epitope I capable of inducing neutralizing
antibodies (41, 42), though, as noted by others, at least one such region (corresponding
FIG 6 Structure of designed C1 immunogen bound to the HCV1 antibody. The crystallographic structure
of full HCV1-C1 complex (A), as well as details of the bound C1 peptide in side view (C), top view (E), and
the HCV1 CDR loops (G), are shown in comparison with the structure of the native linear epitope bound
to HCV1 (B, D, F, and H), which was previously described (6) (PDB code 4DGY). Peptides are shown as
green sticks (with oxygen atoms in red, nitrogen atoms in blue, and sulfur atoms in yellow), and HCV1
antibody is shown as a cartoon with the light chain colored light blue and the heavy chain colored tan.
Key epitope residues for HCV1 binding and  turn structure (L413, G418, and W420), as well as terminal
and cyclization residues, are labeled in panels C and D, and selected HCV1 CDR loops are labeled in
panels G and H. In the top view of the epitope (E and F), side chains are omitted and intrapeptide
hydrogen bonds are shown as black dashed lines.
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to epitope II, which is targeted by the 96-2 MAb) is associated with viral escape (43).
Among these antigens, E2661 and T1 induced the highest levels of H77 neutralizing
antibodies, with T2 and T3 constructs containing the transplanted epitope at aa 629 to
640 yielding lower neutralizing antibody responses.
To assess neutralization breadth, we tested serum neutralization using HCVpps
derived from genotype 1b and 4a isolates (Table 2), which were used previously to
characterize HCV1 MAb neutralization (21). For all constructs, neutralization activity
against these was lower than for H77, suggesting limited neutralization breadth overall.
The T1 design maintained the neutralization of the genotype 1b HCVpps with respect
to E2661, with possible modest improvement. For the designed cyclic constructs,
TABLE 1 X-ray data collection and structure reﬁnement statistics
Parameter Value(s) for HCV1-C1
Data collection
Resolution (Å) 29.49–2.26 (2.29–2.26)
Space group P1
Unit cell
a, b, c (Å) 47.07, 94.54, 126.76
, ,  (°) 91.84, 94.95, 97.91
No. of reﬂections 186,455
No. of unique reﬂections 96,679 (8,406)
Completeness (%) 92.68 (61.00)
Rmergeb 0.069
Reﬁnement
Rwork (%)a,c 21.81 (30.99)
Rfree (%)a,c 26.09 (34.27)
No. of protein atoms 14,030
No. of water molecules 548
RMSDs from ideality
Bond length (Å) 0.012
Bond angles (°) 1.59
Ramachandran plot statistics (%)
Favored 96.1
Allowed 3.6
Forbidden 0.3
aValues in parentheses are statistics for the highest-resolution shell.
bRmerge  hiIhi  Ih/h,iIhi, where Ihi is the ith observation of the reﬂection h, while Ih is its mean
intensity.
cRwork  ||Fo|  |Fc||/|Fo|, where Fc is the calculated structure factor. Rfree is as for Rwork but calculated for
a randomly selected 5% of reﬂections not included in the reﬁnement.
FIG 7 Binding of immunized mouse sera to epitope I. Four mice per group were immunized with
E2-based or peptide construct, and sera were tested using ELISA for binding to a linear epitope I peptide
(aa 409 to 425, H77 sequence) conjugated to BSA, using a coating concentration of 2 g/ml. P values
were calculated using a two-tailed t test (***, P  0.001; ns, not signiﬁcant [P  0.05]).
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neutralization breadth was limited, suggesting that despite robust epitope I-speciﬁc
responses, limited sequence variability within the epitope (I414V for the 1b isolate and
T416S for the 4a isolate [21]) or other variations in viral sequence or ﬁtness reduced the
neutralization capacity of immunized sera against these isolates.
DISCUSSION
Structure-based HCV vaccine design has seen limited success recently reported by
others. One study described structure-based design of scaffolded antigens for HCV to
display an E1 epitope as well as E2 epitope I (44). Though the latter constructs were
tested for binding to the HCV1 antibody, no in vivo results were reported. The designs
resulting from the metaserver methodology described in that study were larger and
distinct from the cyclic designs we produced and tested in vivo. More recently, a study
was reported featuring a cyclic epitope I construct with a different mode of disulﬁde
cyclization than C1 or C2, including epitope residues 412 to 422 rather than 412 to 423
(C1) or 409 to 425 (C2) and no glycan at N417 (45). After mouse immunization with this
antigen, several elicited MAbs were tested for epitope binding and neutralization, but
no measurable neutralization was observed. By employing two distinct design ap-
proaches, scaffolding of the epitope to present the stabilized epitope structure to the
immune system (C1 and C2), and antigen redesign (T1, T2, and T3), we were able to
provide an unprecedented comparison of these widely different design strategies in
vivo for their potential to elicit epitope-speciﬁc and neutralizing antibodies to HCV,
along with structural characterization of a designed immunogen.
Although the bivalent E2 construct we produced (T2) yielded lower neutralizing
antibody responses than the monovalent control (T1) based on H77 50% neutralization
(ID50) values (Table 2), further exploration of this approach may be warranted. One
advantage of this bivalent antigen not considered in the design strategy was the
disruption via mutation of an E2 epitope associated with nonneutralizing antibodies
that includes residue Y632 (28). Furthermore, the absence of HVR1 in T2 and other
truncated constructs is an advantage over E2661, as that region is associated with high
sequence variability and escape from neutralizing antibodies (40). However, its reduced
capacity to induce neutralizing antibodies, and the lack of apparent improvement in
levels of epitope I-speciﬁc antibodies, suggests that the T2 antigen requires further
design to improve presentation of the transplanted epitope, and possibly its stability.
One option in this regard would be design to optimize the E2 core-epitope interface at
aa 629 to 640, which was not performed originally in order to preserve the full epitope
FIG 8 HCV neutralization of immunized mouse sera. Four mice per group were immunized with E2-based
or peptide construct, and sera were tested using the HCVpp assay for genotype 1a neutralization. The
neutralization activity at a serum dilution of 1:64 was normalized with the activity of preimmune serum
and expressed as percentage of neutralization for each animal. Lines indicate mean values for each
group. P values were calculated using a two-tailed t test (*, P  0.05; **, P  0.01; ns, not signiﬁcant [P 
0.05]).
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sequence. Such designs could include removal of the glycan at epitope position N417
via mutation of N417 or S419, in conjunction with other substitutions of non-HCV1
contact residues proximal to E2 core to improve packing and shape complementarity.
Intriguingly, others have recently noted that for another truncated variant of E2 (with
HVR1 to HVR3 removed), high-molecular-weight forms of the protein improve neutral-
izing antibody responses, thus providing an additional route to increase the neutral-
ization potency and breadth of these E2-based designs (46). While we did observe
epitope I-speciﬁc and neutralizing antibodies elicited by our truncated designs, epitope
II and other sites on E2 may indeed be targeted by the neutralizing response; the extent
of epitope I-speciﬁc neutralizing antibodies can possibly be probed in future work
through additional assays, such as inhibition of HCVpp neutralization using epitope I
peptide.
The cyclic antigens we generated highlight the potential of minimal stabilized
antigens to induce neutralizing epitope-speciﬁc antibodies that improve over immu-
nization with the linear peptide. The improvement in immunogenicity does not seem
to be due to improved HCV1 binding afﬁnity, as based on our assays there was no
signiﬁcant change, though other binding assays such as isothermal titration calorimetry
may help to conﬁrm this. As at least one extended epitope I structure is associated with
an antibody with relatively weak neutralization (12), and cyclization would avoid or
TABLE 2 Serum neutralization in immunized micea
Immunogen Mouse no.
% Neutralization
H77 ID50H77 (1a) 1b 4a
Linear 1 0 64
2 0 64
3 0 64
4 0 64
C1 1 96 0 0 720
2 40 23 0 64
3 30 0 0 64
4 53 0 0 64
C2 1 62 20 4 70
2 0 0 0 64
3 43 23 0 64
4 65 37 0 110
T1 1 97 64 0 5,000
2 99 92 18 5,000
3 97 0 0 890
4 95 91 20 870
T2 1 88 0 18 100
2 88 15 24 190
3 98 87 0 5,000
4 67 0 8 64
T3 1 95 33 16 425
2 99 27 19 5,000
3 80 28 15 75
4 89 23 45 400
E2661 1 99 10 0 5,000
2 99 10 23 3,470
3 99 70 0 5,000
4 99 10 28 5,000
aPercent neutralization was measured using HCV pseudoparticle (HCVpp) assays and is shown for a serum
dilution of 1:64, with HCVpp representing genotypes 1a (isolate H77), 1b (isolate 1b-#2), and 4a (isolate
4a-MJ). Dilution levels corresponding to 50% neutralization (ID50) were calculated for H77 by curve ﬁtting in
GraphPad Prism software. Shading indicates 50% neutralization at the 1:64 dilution or an H77 ID50 of
100. Due to low H77 neutralization, genotype 1b and 4a HCVpp neutralization of linear peptide-
immunized mice was not tested.
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disfavor such a conformation, it is possible that constraining the epitope conformation
could affect the quality of the antibody response. However, given the improvement in
epitope-speciﬁc antibody titers from cyclic designs, other factors, such as improved
serum stability and half-life of the cyclic designs, may be responsible. Though the levels
of neutralizing antibodies induced by the cyclic epitopes were relatively low, compared
with those obtained with sera from E2661-immunized animals, and exhibited limited
neutralization breadth, a number of options are available to improve neutralizing
antibody response, including display of the cyclic immunogens on virus-like particles or
nanoparticles (47). Heterologous prime-boost vaccination, with E2 or E1E2 protein as
the prime followed by boost with cyclic epitope I to focus the response to that portion
of E2, as utilized by others for HIV vaccination (48), may also improve levels of epitope
I-speciﬁc neutralizing antibodies.
The limited neutralization breadth elicited by the cyclic constructs is possibly related
to recent observations of HCV neutralization where certain isolates exhibit broad nAb
resistance, which was correlated with overall viral infectivity for a large panel of HCVpps
(49). In another study, non-epitope E2 residues affecting coreceptor binding appeared
to be responsible for resistance (50), while others have noted variability in neutraliza-
tion with MAbs targeting epitope I, despite conserved epitope sequence (22). A
deep-sequencing analysis including patients undergoing HCV1 MAb immunotherapy
revealed E1 and E2 positions outside epitope I with relatively high mutation rates,
suggesting a possible direct or indirect role in evading antibody targeting of that
epitope (51). In light of the relatively low but detectable levels of H77 neutralization, it
is possible that even modest (2- to 4-fold) increases in resistance in the 1b and 4a
HCVpps tested led to a lack of measurable neutralization by the sera from animals
immunized with cyclic peptides, and modiﬁcations in immunogen display as noted
above would lead to more detectable and robust neutralization breadth. HCVpps
representing a larger set of isolates can be included in follow-up studies of these
designs to provide more support of neutralization breadth or lack thereof.
Further design of the cyclic constructs may also yield improved responses. Charac-
terization of MAbs induced by C1 or C2 vaccination, via alanine scanning mutagenesis,
afﬁnity measurements, or crystallography, may yield information regarding the induced
repertoire and possible molecular details underlying the observed difference between
epitope I-speciﬁc binding and neutralization, for instance, MAb binding to portions of
the epitope that are inaccessible in the context of E2 or the virion. Such characterization
of C1 and C2-elicited MAbs, which was utilized recently for another cyclic epitope I
design as noted above (45), could indicate the basis of neutralization in immunized sera
from our constructs and inform second-generation designs of one or both of those
antigens. Additionally, as glycosylation or mutation at N415 is associated with escape
from HCV1 (25, 51) and other MAbs (9), addition of a glycan at N415, in addition to
N417, may induce antibodies capable of targeting this epitope with a binding footprint
that does not include N415 while maintaining binding to the conserved residues L413
and W420. Given the glycan sequons of NxT and NxS, simultaneous glycosylation at
N415 and N417 is possible only in a synthetic peptide (such as the ones described here)
rather than an expressed protein antigen. Recently described structural characterization
of an epitope I-targeting MAb, HC33.1, that can neutralize the glycan-shifted N417S
variant and engages the epitope in a unique extended conformation may lead to
additional scaffolded or stabilized designed antigens (30). We have shown in this study,
using the HCV1-bound epitope I conformation, that such an approach is possible and
merits further investigation.
MATERIALS AND METHODS
Scaffold selection. A set of 7,626 potential scaffold structures was downloaded from the Protein
Data Bank (PDB) (33) in February 2013. All structures were monomeric (one protein chain in the biological
assembly), expressed in Escherichia coli, and determined by X-ray crystallography and contained fewer
than 200 residues. The structural alignment program FAST (34) was used to identify any structurally
similar region to epitope I (PDB code 4DGY, chain A) within each structure. Approximately half of the
structures (4,200) contained regions identiﬁed by FAST as structurally similar to the epitope; these results
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were analyzed to determine length of match, root mean square distance (RMSD) to the epitope (both
computed by FAST), and accessibility for antibody binding. The last value was determined by counting
the atomic contacts (4.0 Å) between the HCV1 MAb and scaffold (excluding the epitope-matching
residues) after superposing the scaffold onto the epitope in the HCV1-epitope complex structure using
FAST.
Protein expression and puriﬁcation. The nucleic acid sequences encoding HCV E2 (genotype 1a
isolate H77; GenBank accession number NC004102) aa 384 to 661 (referred to as E2661) and its designed
truncated constructs (T1, T2, and T3) were synthesized and cloned into a mammalian expression vector,
pcDNA3.1 (Life Technologies), in frame with an N-terminal histidine (His) tag. Cloned vectors were
transfected into HEK-293T cells using Lipofectamine 2000 (Life Technologies) as described by the
manufacturer. Cells were grown to conﬂuence in T150 ﬂasks in 15 ml of Dulbecco modiﬁed Eagle
medium (DMEM) with 10% fetal bovine serum (FBS). Thirty micrograms of DNA was mixed with 75 l of
Lipofectamine 2000, and the mixture was added to the cells for overnight incubation at 37°C. Medium
was removed 24 h posttransfection and replaced with fresh complete DMEM. A 3 mM concentration of
sodium butyrate (Sigma-Aldrich) was added to the medium 48 h posttransfection, and the supernatants
were harvested after an additional 24-h incubation. Filtered supernatants were mixed with nickel-
nitrilotriacetic acid (Ni-NTA) agarose (Life Technologies) for 2 h at room temperature, and proteins were
eluted with 250 mM imidazole (Sigma-Aldrich). Eluted proteins were dialyzed against phosphate-
buffered saline (PBS), concentrated, and stored in single-use aliquots at 80°C. Protein integrity and
purity were evaluated by SDS-PAGE with Coomassie staining and by Western blotting using mouse
anti-His antibody.
Peptides. Linear and cyclized peptides including the H77 epitope I sequence (QNIQLINTNGSWHI
NSTK and CQLINTNGSWHINCK) were produced at New England Peptide (Gardner, MA), conjugated to
bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) carrier protein via glutaraldehyde at
the C-terminal lysine side chain. For peptides without backbone cyclization, N termini were modiﬁed via
acetylation to improve coupling and prevent N-terminal glutamine conversion to pyroglutamic acid (in
the case of linear peptide). Peptides produced for immunogenicity studies were N-glycosylated at the
position corresponding to N417 with the N-acetylglucosamine (GlcNAc) glycan.
ELISA. Ninety-six-well plates were coated with antigens (peptide, E2661, or E2 truncations) at a
concentration of 2 g/ml, followed by incubation overnight at 4°C. Mouse serum or puriﬁed antibody
was added to the 96-well plates and incubated for 1 h at room temperature. Antibody binding was
detected with anti-human alkaline phosphatase secondary antibody and p-nitrophenyl phosphate
disodium salt (PNPP) substrate.
SPR. All surface plasmon resonance (SPR) experiments were performed using a Biacore T100
instrument (GE Healthcare). Soluble BSA (New England BioLabs), C2 peptide-BSA, C1 peptide-BSA, and
the linear peptide-BSA in 10 mM sodium acetate, pH 4.0, were immobilized on a CM5 sensor chip via a
standard amine coupling procedure at densities of 1,322 response units (RU) to ﬂow cell 1, 796 RU to ﬂow
cell 2, 124 RU to ﬂow cell 3, and 101 RU to ﬂow cell 4, respectively. HBS-X buffer (10 mM HEPES, 150 mM
NaCl, 0.05% Tween) was used as a running buffer. BSA coupled to the sensor chip in ﬂow cell 1 was used
as the negative-control surface. A concentration series of HCV1 MAbs (125 to 1.9 nM) in running buffer
was injected over ﬂow cells 1 to 4 for 60 s per injection and allowed to dissociate for 300 s. Between
binding cycles, the sensor chip surface was regenerated by washing with 2 M NaCl. Kinetic parameters
and afﬁnity constants for all interactions were calculated using a kinetic model for bivalent analytes (as
HCV1 was in IgG rather than Fab format) with Biacore T100 evaluation software 2.0.4.
X-ray crystallography. HCV1 Fab was separated from the Fc by papain using standard protocols,
puriﬁed by size exclusion chromatography on a GE Superdex S200, concentrated to 10 mg/ml in 20 mM
Tris–100 mM NaCl (pH 8.3), and incubated with a 10-fold excess of the C1 peptide (CQLINTNGSWHINCK).
Crystals formed after 1 week by vapor diffusion in 0.2 M calcium acetate, 0.1 M morpholineethanesulfonic
acid (MES; pH 6.0), and 20% polyethylene glycol 4000 (PEG 4000) at a drop ratio of 1:1. Glycerol was
added at 20% as a cryoprotectant, and data were collected at the Stanford Synchrotron Radiation
Lightsource, beamline 9-2, and the Advanced Photon Source, beamline 23-ID-D. The data were inte-
grated by XDS at a 2.26-Å resolution, phased using molecular replacement by Phaser, built using Coot,
and reﬁned by Phenix reﬁne and Refmac (52–55).
Modeling of HCV1 MAb bound to E2. Modeling of HCV1 MAb bound to E2 at residues 412 to 423
was performed by aligning the HCV1-epitope I complex (PDB code 4DGY) onto the E2 core structure (PDB
code 4MWF, chain D) using root mean square ﬁtting of the backbone atoms of shared E2 residue N423.
The FloppyTail algorithm in Rosetta (56) was then used to perform minimization of HCV1-epitope I in the
context of E2 core, to reduce clash between HCV1 and E2 core, treating the backbone of residue 423 as
a ﬂexible hinge. One hundred models were generated, of which the top model was selected based on
Rosetta score and paucity of MAb contacts with E2 core (as HCV1 targets a linear epitope, extensive
contacts with E2 core are not likely, as supported by a global alanine scanning study with other
antibodies targeting epitope I [28]). HCV1 was ﬁt by backbone superposition of epitope I residues onto
residues 629 to 640 of E2 core to model its engagement of the transplanted epitope.
In vivo studies. CD-1 mice (Charles River) were injected intraperitoneally with puriﬁed protein mixed
with Sigma Adjuvant System (SAS) adjuvant (Sigma-Aldrich) with 50 g of prime immunization and four
10-g boosts given weekly, except for a gap of 2 to 3 weeks between the second and third boosts.
Animals were sacriﬁced approximately 10 days after ﬁnal injection, and sera were collected for neutral-
ization and binding assays.
HCV transfection, infection, and neutralization assays. Pseudovirus was generated by using a
replication-defective HIV backbone containing a ﬁreﬂy luciferase gene to direct luciferase expression in
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target cells (pNL4-3.Luc.RE, obtained through the AIDS Research and Reference Program, Division of
AIDS, NIAID, NIH, from Nathaniel Landau). The nucleic acid sequences encoding HCV E1E2 glycoprotein
from isolates H77 (genotype 1a), 1b-#2 (genotype 1b), and 4a-MJ (genotype 4a), GenBank accession
numbers NC_004102, GQ259488, and GQ379230, respectively, were cloned into pcDNA3.1 vector as
described previously (21). The pcDNA-E1E2 vectors were cotransfected with pNL4-3.Luc.RE into
HEK-293T cells using Lipofectamine 2000 (Life Technologies). Pseudoviral particles were harvested 48 to
72 h posttransfection, concentrated using a Centricon 70 concentrator (Millipore), aliquoted, and stored
frozen at 80°C. Before assessing antibody neutralization, a titration of HCVpps was performed on Hep3B
cells to determine what volume of virus generated 50,000 cps in the infection assay. The appropriate
volume of HCVpps was preincubated with various dilutions of mouse serum or HCV1 for 1 h at room
temperature before addition to Hep3B cells. After incubation for 72 h (31), infection was quantiﬁed by
luciferase detection (Bright-Glo reagent; Promega) and read in a Victor 3 plate reader (PerkinElmer) for
light production.
Figures. Figures showing molecular structures were generated using PyMOL (Schrodinger, LLC), and
plots of ELISA and neutralization data were generated using GraphPad Prism. The epitope I sequence
logo was generated using the WebLogo program (32).
Accession number(s). The structure of the designed C1 immunogen in complex with the HCV1 MAb
has been deposited in the PDB under accession code 5KZP.
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